This article details the “10-year-long saga” concerning whether Dolly the Cloned Sheep, the first mammal cloned from an adult cell, could be patented. In 2014, the Court of Appeals for the Federal Circuit ruled against granting a patent to Dolly’s creators in In re Roslin Institute. Though Dolly’s creators did receive a patent on the method used to create Dolly, they were denied a patent on Dolly herself.
The Court of Appeals aligned its decision with past cases, such as Association for Molecular Pathology v. Myriad Genetics and even Diamond v. Chakrabarty. Essentially, Dolly could not be patented because she was identical to animals found in nature, her “genetic identity to her donor parent render[ed] her unpatentable.”
The article went on to discuss the broader potential implications of the decision as related to biomedical research. As a result of the case, some feared that if the Patent and Trademark Office is unwilling to grant patents on human-made products that are genetically the same as products of nature, then personalized medicine will not continue to be researched. This could have detrimental effects on ideas like cells modified to resemble human stem cells or lab-grown organs. Other scholars noted that perhaps the case would not have such far-reaching consequences, due to the fact that this case was broadly drafted.